News
Press Releases
May 18, 2023
Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time Rejuva platform and genet...
Read MoreMay 9, 2023
LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it will be presenti...
Read MoreMay 2, 2023
LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, a commercial-stage, organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it...
Read MoreApr 24, 2023
Registry subjects will initially enroll in multiple hospitals in Germany, where the Revita System has already obtained a CE Mark and reimbursement through the NUB reimbursement process. LEXINGTON, Mass.--(BUSINESS WIR...
Read MoreFeb 7, 2023
Der erste Patient mit Typ-2-Diabetes (T2D) erhielt Revita®in Deutschland, wo das Revita DMR System™über eine CE-Kennzeichnung und Kostendeckung im Rahmen des NUB-Erstattungsprozesses verfügt ImRahmen des 25. ...
Read MoreFeb 7, 2023
First patient in Germany with Type 2 Diabetes (T2D) received Revita® in Germany, where the Revita DMRSystem™ has a CE Mark and insurance coverage through the NUB reimbursement process Live demonstration of a Re...
Read MoreJan 31, 2023
Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort
Revita-T2Di is an open-label cohort evaluating Revita® in patients with insulin-treated Type 2 Diabetes Revita in the T2Di cohort has been observed to be well tolerated, with clinically meaningful improvements in...
Read MoreDec 5, 2022
POC efficacy data in rodents shows that a novel adeno-associated virus (AAV) pancreatic gene therapy platform can confer dose-dependent effects on improving insulin production and reducing blood sugar Dose-depend...
Read MoreNov 2, 2022
Newly formed Erase T2D task force comprises leading scientists and pioneering scientific research to elucidate the role of the duodenum in type 2 diabetes and metabolic control Fractyl Health-supported research pr...
Read MoreMay 22, 2022
Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes
Patients treated with Revita experienced a 0.8%-point reduction in HbA1c along with a 33% improvement in markers of insulin sensitivity three months after undergoing the procedure Markers of insulin production cap...
Read MoreThe press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.
Media Contact: Beth Brett, Corporate Communications
Bbrett@fractyl.com , +1 (720) 656-6544
In the News
Feb 8, 2022
Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System
Read MoreFeb 1, 2022
Read MoreMay 21, 2021
How Fractyl is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections
Drug Delivery Business News
Read MoreApr 27, 2021
Fractyl gets FDA breakthrough nod for intestinal resurfacing in type 2 diabetes
BioWorld
Read MoreMar 22, 2021
Will Fractyl be Successful in Eliminating the Need for Daily Insulin?
MDDI Online
Read More